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Knockdown of stem cell 
regulator Oct4A in ovarian cancer 
reveals cellular reprogramming 
associated with key regulators of 
cytoskeleton-extracellular matrix 
remodelling
Chantel Samardzija1, David W. Greening2, Ruth Escalona1,3,4, Maoshan Chen2, 
Maree Bilandzic3, Rodney Luwor5, George Kannourakis4,6, Jock K. Findlay1,3 & 
Nuzhat Ahmed1,3,4,6
Oct4A is a master regulator of self-renewal and pluripotency in embryonic stem cells. It is a well-
established marker for cancer stem cell (CSC) in malignancies. Recently, using a loss of function studies, 
we have demonstrated key roles for Oct4A in tumor cell survival, metastasis and chemoresistance 
in in vitro and in vivo models of ovarian cancer. In an effort to understand the regulatory role of 
Oct4A in tumor biology, we employed the use of an ovarian cancer shRNA Oct4A knockdown cell 
line (HEY Oct4A KD) and a global mass spectrometry (MS)-based proteomic analysis to investigate 
novel biological targets of Oct4A in HEY samples (cell lysates, secretomes and mouse tumor 
xenografts). Based on significant differential expression, pathway and protein network analyses, 
and comprehensive literature search we identified key proteins involved with biologically relevant 
functions of Oct4A in tumor biology. Across all preparations of HEY Oct4A KD samples significant 
alterations in protein networks associated with cytoskeleton, extracellular matrix (ECM), proliferation, 
adhesion, metabolism, epithelial-mesenchymal transition (EMT), cancer stem cells (CSCs) and drug 
resistance was observed. This comprehensive proteomics study for the first time presents the Oct4A 
associated proteome and expands our understanding on the biological role of this stem cell regulator in 
carcinomas.
Ovarian cancer (OC) is the most lethal of all the gynaecological malignancies with a five-year mortality rate of 
> 70%1. This poor outcome is due to the fact that the majority of OC cases are diagnosed at an advanced meta-
static stage when the disease is no longer confined to the ovaries and is typically characterised by a widespread 
peritoneal dissemination and ascites1. While cytoreductive surgery and chemotherapy are initially effective in 
treating the disease in the short-term, relapse in advanced-stage patients is inevitable and almost all patients 
develop highly aggressive recurrent disease within few months which is intrinsically resistant to chemotherapy. 
Recent observations suggest OC recurrence may be driven by a sub-population of tumor cells which exhibit 
stem cell-like traits2,3. These cells, termed cancer stem cells (CSCs) not only display increased self-renewal char-
acteristics as seen in embryonic stem cells (ESCs), but also exhibit tumorigenic survival properties and have 
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been implicated in chemoresistance4,5. The molecular mechanisms which drive CSC-mediated OC progression, 
chemoresistance and recurrence have not yet been fully elucidated.
The presence and importance of CSCs in different cancer scenarios including OC has been accumulating 
for the last ten years. However, the origin and the biological identity of CSCs associated proteome still remains 
unclear. Several potential indirect mechanisms of CSC regulation have been proposed; of particular interest are 
the Notch, Hedgehog, Janus activated kinase/Signal transduction and activator of transcription (JAK/STAT), 
anti-apoptotic and drug-resistant pathways5–7. Others mechanisms include; malignant transformation of (i) adult 
stem cells into CSCs8,9; or (ii) multipotent progenitor or transit amplifying cells into CSCs9,10; or (iii) differenti-
ated cells into CSCs which acquire stem cell characteristics after loss of differentiation ability8. A recent study has 
demonstrated the existence of equilibrium between CSCs and non-CSCs in a tumor with the balance being tipped 
towards CSCs in response to microenvironmental stimuli11,12. These candidate-based approaches though interest-
ing does not elucidate the exact mechanism of CSC regulation which is absolutely essential to design CSC-based 
therapeutics required to abrogate clinically the residual tumor source which initiates recurrence.
Oct4 (Oct3/4, POU5F1) is a transcription factor which maintains self-renewal and pluripotency in embry-
onic stem cells and primordial germ cells13–15. The POU5F1 gene encodes two transcript variants, POU5F1A 
(Oct4A) and POU5F1B (Oct4B) which consist of 360 and 255 amino acids respectively, but share a common 
carboxyl-terminus of 225 amino acids13,16. Oct4B is generally localised in the cytoplasm, while Oct4A is localized 
mainly in the nucleus and has been associated with the maintenance of an undifferentiated state and stem cell 
properties of embryonic stem cells as well as primordial germ cells15,16. In addition, Oct4A expression has been 
shown as a diagnostic marker in germ cell tumors17. Recent studies have demonstrated elevated expression of 
Oct4 in several somatic tumors including breast, bladder, prostate, lung as well as of ovarian origin13. However, 
most studies have investigated Oct4 as a tumor marker; and only a handful of studies have reported expres-
sion analyses discriminating the Oct4A and Oct4B isoforms13,18. Hence, it remains undetermined whether Oct4 
expression in most tumor groups is specific for stemness and/or CSCs, or it is just another tumorigenic marker 
used for expression analysis. Recently, transcriptomic, genomic and systems biology methods have identified 
Oct4 to be associated in an intricate regulatory network with Sox-2 and Nanog which results in the activation of 
transcription of genes required for pluripotency19,20. It is well established that the mRNA levels in a cellular system 
do not necessarily reflect protein abundance, and post-translational modification of proteins rapidly modulate 
protein activity and transduce signals crucial in maintaining stemness, differentiation, metastasis and drug resist-
ance. However, the post-translational event of a cellular network which is important to map the regulatory mech-
anism of pluripotency or stemness cannot be identified by genomic and epigenomic studies and still remains 
obscured21. Hence elucidating the proteome of CSCs represents a rich informative repertoire of understanding 
cancer metastasis and recurrence.
MS-based proteomics has essentially changed the way by which malignant initiation and progression is inves-
tigated by its ability to identify and monitor thousands of proteins and post-translational modifications22. In 
OC, biomarker research for early-stage screening has become one of the most exciting uses for MS-based pro-
teomics analysis23,24. Clinical specimens including tumors, ascites and serum samples have been assessed for 
distinct protein/peptide signatures to identify novel proteins which may assist in disease detection25. Recently, 
the methodology has also been used to identify novel therapeutic targets for recurrent diseases based on protein 
signatures of chemotherapy treated patients26. MS-based proteomics of CSCs therefore offers an advantage to 
study post-transcriptional regulation and signalling network of CSCs associated with self-renewal, differentia-
tion, tumor progression as well as recurrence due to drug resistance. At the same time it provides a platform to 
study the proteome of a specific CSC marker in a targeted and high-throughput manner that allows dissection of 
crucial CSC-specific biology. It also provides avenues in dissecting fundamental differences between CSCs and 
adult stem cells, CSCs and embryonic stem cells and CSCs and pluripotent stem cells.
Using a large-scale, label-free quantitative MS-based proteomic profiling approach, this study for the first time 
identified novel proteins and/or peptides which are associated specifically with Oct4A in the HEY ovarian cancer 
cell line and an associated mouse xenograft model. By identifying specific protein targets and select protein net-
works associated with differential expression of Oct4A, this study aimed to contribute to our knowledge of the 
biological traits driven specifically by Oct4A in OC and potentially other tumor models.
Methods and Materials
Cell lines. The development of the HEY vector control and HEY Oct4A KD cell lines has been described 
previously27. SKOV3 and OVCAR5 cell lines have also been described previously27. Cells were grown in RPMI-
1640 growth media supplemented with 10% (v/v) heat inactivated FBS (Thermo Fisher Scientific), 2 mM 
L-glutamine (Invitrogen, Australia) and an antibiotic combination of 1% (v/v) streptomycin and penicillin 
(Invitrogen, Australia). Cells were maintained at 37 °C in the presence of 5% CO2 and routinely checked for 
mycoplasma infection.
Treatment of ovarian cancer cell lines with paclitaxel and cisplatin. Ovarian cancer cell lines were 
treated with paclitaxel and cisplatin at GI50 concentrations (50% growth inhibitory concentrations) for 72 hrs at 
37 °C in the presence of 5% CO2 as described previously27. For paclitaxel treatment, HEY cells were treated with 
1 ng/ml while SKOV3 and OVCAR5 cell lines were treated with 0.5 ng/ml. For cisplatin treatment of OVCAR5 
cells a GI50 concentration of 3 μ g/ml of cisplatin was used.
Animal studies. Animal studies were carried out as described previously27.
Whole cell lysates and tumor xenograft sample preparation. HEY vector control and HEY 
Oct4A KD cells were maintained in RPMI-1640 growth media as described previously27. After reaching > 70% 
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confluence, cells were washed three times in ice-cold PBS. Protein lysis buffer4% (w/v) SDS, 20% (v/v) glycerol 
and 0.01% (v/v) bromophenol blue, 0.125 M Tris-HCl, pH 6.8 containing complete EDTA-free protease inhibitor 
cocktail (Roche) and 1 mM Dithiothreitol was added directly to confluent cells and cells were then sonicated 
for 180 sec. Collected samples were incubated at 95 °C for 20 min and 60 °C for 2 hrs before being centrifuged at 
25,000 × g for 30 min. The supernatant was stored at - 80 °C until required.
For tumor xenograft samples, tumors were produced by intraperitoneal (i.p) injection of HEY Oct4A KD and 
HEY vector control cells into Balbc/c nude mice as previously described27. Sections of tumor xenografts were 
homogenised in lysis buffer and sonicated for 180 sec. Homogenates were then incubated at 95 °C for 20 min and 
60 °C for 2 hrs before being centrifuged at 25,000 g for 30 min. Each supernatant sample was stored at - 80 °C until 
required.
Secretome Sample Preparation. Conditioned media (CM) collected from sub-confluent (80%) HEY 
vector control and HEY Oct4A KD cells grown in RPMI-1640 (serum-free) were centrifuged (500 × g for 5 min, 
2000 × g for 10 min) CM concentrated by centrifugal ultrafiltration as described previously28. Each concentrated 
fraction was stored at - 80 °C until required.
Protein Quantification. The protein content of whole cell lysate and secreted cellular preparations was 
estimated by one-way dimensional SDS-PAGE/SYPRO Ruby protein staining densitometry as previously 
described26,28,29.
Proteomic Analysis. Proteomic analyses were performed as previously described29 in biological replicates 
(n = 4) and technical duplicates (n = 2). Cell/tumor lysates and secreted sample preparations (10 μ g protein) were 
lysed in SDS sample buffer(2% (w/v), 125 mM Tris-HCl, pH 6.8, 12.5% (v/v) glycerol, 0.02% (w/v) bromph-
enol blue), electrophoresed by short-range SDS-PAGE (10 × 6 mm), and visualized by Imperial Protein Stain 
(Invitrogen). Individual samples were excised, destained, reduced, alkylated, and trypsinized as described26. A 
nanoflow Ultra Performance Liquid Chromatography (UPLC) instrument (Ultimate 3000 RSLCnano, Thermo 
Fisher Scientific) was coupled on-line to a Linear Trap Quadropole (LTQ) Orbitrap Elite mass spectrometer 
(Thermo Fisher Scientific) with a nanoelectrospray ion source (Thermo Fisher Scientific). Peptides were loaded 
(Acclaim PepMap100, 5 mm × 300 μ m i.d., μ -Precolumn packed with 5 μ m C18 beads, Thermo Fisher Scientific) 
and separated (Acquity UPLC M-Class Peptide BEH130, C18, 1.7 μ m, 75 μ m × 250 mm, Waters). Data was 
acquired using Xcalibur software v2.1 (Thermo Fisher Scientific).
Database searching and protein identification. Raw data were processed as described previously29 
using Proteome Discoverer (v2.1, Thermo Fisher Scientific). MS2 spectra were searched with Mascot (v2.4, Matrix 
Science), and Sequest HT (v2.1, Thermo Fisher Scientific) against a database of 133,798 ORFs (UniProtHuman, 
Apr 2016). Peptide lists were generated from a tryptic digestion with up to two missed cleavages, carbamidometh-
ylation of cysteines as fixed modifications, and oxidation of methionines and protein N-terminal acetylation as 
variable modifications. Precursor mass tolerance was 10 ppm, product ions were searched at 0.06 Da tolerances, 
minimum peptide length defined at 6, maximum peptide length 144, and max delta CN 0.05. Peptide spec-
tral matches (PSM) were validated using Percolator based on q-values at a 1% false discovery rate (FDR). With 
Proteome Discoverer, peptide identifications were grouped into proteins according to the law of parsimony and 
filtered to 1% FDR. Scaffold Q + S (v4.5.3, Proteome Software Inc) was employed to validate MS/MS-based pep-
tide and protein identifications from database searching. Initial peptide identifications were accepted if they could 
be established at greater than 95% probability as specified by the Peptide Prophet algorithm. Protein probabilities 
were assigned by the Protein Prophet algorithm. Protein identifications were accepted, if they reached greater 
than 99% probability and contained at least 2 identified unique peptides. These identification criteria typically 
established < 1% false discovery rate based on a decoy database search strategy at the protein level. Proteins that 
contained similar peptides and could not be differentiated based on MS/MS analysis alone, were grouped to 
satisfy the principles of parsimony. Contaminants and reverse identification were excluded from further data 
analysis. UniProt was used for protein annotation.
Label-free spectral counting, differentially expression and functional analysis. Significant spec-
tral count (SpC) and Ratio of spectral count (Rsc) were determined as previously described29–31. The relative 
abundance of a protein within a sample was estimated using normalized SpC, where for each individual protein, 
significant peptide MS/MS spectra (i.e., ion score greater than identity score) were summated, and normalized 
by the total number of significant MS/MS spectra identified in the sample. The number of significant assigned 
spectra for each protein was used to determine protein differences between HEY Oct4A KD and the HEY vector 
control. For each protein the Fisher’s exact test was applied to significant assigned spectra. The resulting p-values 
were corrected for multiple testing using the Benjamini-Hochberg procedure32 and statistics performed as pre-
viously described26. Differentially expressed proteins were identified using the criteria: Rsc > ± 1.8 and p < 0.05.
Protein-protein interaction analyses by STRING 10.0. Identification of entriched protein networks in 
cell lysates, secretomes and xenografts of Oct4AKD vs vector control was performed by STRING 10.0 software33. 
Clustering of proteins between samples was performed by Pearson correlation between samples using the pro-
tein profiles and visualized using gplots (https://cran.r-project.org/web/packages/gplots/index.html) package in 
R software. Raw data set of proteins identified in vector control and HEY KD samples (cell lysates, secretomes and 
xenografts) is described in Supplementary Table 1.
RNA extraction and Real-Time (RT) PCR. Quantitative real-time PCR was performed as described pre-
viously27. Relative quantification of gene expression was normalized to 18S and calibrated to the appropriate 
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control sample using the SYBR Green-based comparative CT method (2-ΔΔCt). The primer set of Oct4A, vimen-
tin (VIM), plectin (PLEC), TUBB2A and the house keeping gene 18S are described in Table 1.
Immunohistochemistry of mouse tumors. Immunohistochemistry analysis of mouse tumors was 
performed as described previously4,5,27. Briefly, formalin fixed, paraffin embedded 4 μ m sections of the xeno-
grafts were dewaxed with Ventana EZ Prep and endogenous peroxidase activity was blocked using the Ventana’s 
Universal DAB inhibitor. Primary antibodies against Oct4, PLEC, VIM and TUBB2A were diluted accord-
ing to the instruction provided by the manufacturer and sections were stained using a Ventana Benchmark 
Immunostainer (Ventana Medical Systems, Inc, Arizona, USA). Detection was performed using Ventana’s Ultra 
View DAB detection kit (Roche/Ventana, Arizona, USA) using the method described previously4. Tumor sections 
were counter stained with Ventana Haematoxylin and Blueing Solution. Immunohistochemistry images were 
captured and analysed by using Aperio ImageScope v12.1.0.5029 as described previously27.
Results
Proteome analysis of HEY vector control and Oct4A KD samples. We have recently shown knock-
down of Oct4A in a HEY cell line by small hairpin (sh)RNA technology27,34. Knockdown of Oct4A in the HEY cell 
line (Oct4AKD) was confirmed at the protein level by Western blot and immunofluorescence and at the mRNA 
level by Quantitative Real Time Polymerase Chain Reaction (RT-PCR)27,34. MS-based proteomics analysis on 
vector control and Oct4A KD cells showed a total of 836 proteins to be up regulated in HEY Oct4A KD cellu-
lar samples compared to HEY vector control samples, while 666 cellular proteins were down regulated in HEY 
Oct4A KD samples (biological n = 4, technical duplicate) (Fig. 1). For secreted proteins, a total of 430 proteins 
were up-regulated in HEY Oct4A KD samples compared to HEY vector control, while 256 proteins were down 
regulated. In mouse xenograft tumors, 198 proteins were up regulated in HEY Oct4A KD samples compared to 
HEY vector control samples, while 1247 proteins were down-regulated (Fig. 1).
Protein selection criteria. Following data collection and bioinformatics analyses, proteins which were not 
differentially expressed (p < 0.05) in HEY Oct4A KD samples when compared to HEY vector control samples 
were eliminated. Proteins identified as keratins were also removed from analysis based on known contaminants 
involved in proteomics analysis35. Proteins which had no known protein accession number were also excluded 
based on the fact that they could not be identified. Other exclusion criteria included any protein identified as a 
peptide fragment, a putative uncharacterised protein or those which are cDNA-like in nature. This was based 
on the fact that an accurate protein function may not be identified for these specific peptides. Proteins detected 
in tumor xenograft samples which were related to skeletal muscle were also excluded from the study based on 
likelihood of skeletal muscle contamination during tumor xenograft excision. An outline of the protein selection 
process is described in Fig. 1.
A correlation plot between the samples is presented in Fig. 2. This cluster and normalised heat map analy-
sis revealed that there was a high correlation between different samples (i.e., cell lysates, xenograft lysates and 
secreted). HEY vector control and Oct4A KD cell samples were most similar in expression profiles, while similar-
ities were identified in cell and xenograft lysates and secreted samples. These protein expression cluster analyses 
highlight key differences in protein expression between HEY vector control and Oct4A KD sample subsets.
Proposed protein functions of differentially expressed HEY Oct4A KD cellular proteins. Down 
regulated cellular proteins in HEY Oct4A KD cells compared to Oct4A vector control cells. From the selection 
criteria stipulated in Fig. 1, a total of 18 cellular proteins were identified to be differentially down regulated in 
HEY Oct4A KD samples when compared HEY vector control samples (Fig. 1). When classified according to their 
cellular function, proteins which fit into the categories of cytoskeletal regulation, EMT and cellular metabolism 
constituted 16.7% and were identified as the most frequently down-regulated proteins in HEY Oct4A KD cellu-
lar samples (Table 2, Fig. 3a). This was followed by proteins which were related to drug resistance and cellular 
migration/motility which constituted 11.1% of each category, followed by protein transport, immune response, 
prognosticator of survival, post-translational modifications, and cellular adhesion which constituted 5.6% of each 
category of down regulated proteins (Table 2, Fig. 3a). Of all the identified down regulated cellular proteins, the 
cytoskeleton-related Tubulin beta-2A chain protein (TUBB2A) was the most abundantly down regulated (Rsc 
-42.9), followed by the EMT-related protein 14-3-3ε (YWHAE) (Rsc -10.0). Other down regulated cellular 
Gene Symbol Accession no. Primer sequences from 5′-3′
Size 
(bp)
Rn18S NR_003286.1 Forward GTAACCCGTTGAACCCCATT  Reverse CCATCCAATCGGTAGTAGCG 153
Oct4A NM_002701.4 Forward CTCCTGGAGGGCCAGGAATC  Reverse CCACATCGGCCTGTGTATAT 381
VIM NM_003380 Forward CCTACAGGAAGCTGCTGGAA  Reverse GGTCATCGTGATGCTGAGAA 198
PLEC NM_201384 Forward TACTACCGCGAGAGTGCAGA  Reverse TCCTTGATGGCGTTGATGTA 212
TUBB2A NM_001069.2 Forward CTTCGGCCAGATCTTCAGAC  Reverse GAGAGTGGGTCAGCTGGAAG 176
Table 1.  Human oligonucleotide primer sequences for quantitative real-time PCR.
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Figure 1. Schematic diagram of the methodology used to obtain protein lists from HEY Oct4A KD 
samples. HEY vector control and HEY Oct4A KD cells were prepared as whole cell lysate (n = 4), secretome 
(n = 4) and xenograft tumor samples (n = 4). Samples were solubilised, separated by short-range SDS-PAGE 
and subjected to in-gel reduction, alkylation, and tryptic digestion. Extracted peptides were fractionated and 
identified using mass spectrometry analysis, data processing database searching, informatics and protein 
annotation. Relative protein abundance was determined by estimating the ratio of normalised spectral counts 
(Rsc) between HEY Oct4A KD samples and HEY vector control samples for each protein. To determine the 
classification of proteins in response to Oct4A we applied a stringent analysis filtering criteria. The number of 
proteins which met the selection criteria for each HEY Oct4A KD sample group is listed.
Figure 2. Characterisation of HEY Oct4A subsets reveal correlation between sample subsets in response to 
Oct4A expression. Correlation matrix of cell lysates (CL), tumor xenografts (XN), and secretomes (SC) samples 
representing differential abundance based on normalised spectral count (SpC) values between HEY Oct4A KD 
and HEY vector control samples. Correlation expression profile reveals that each individual sample represents 
clear distribution and similarity with other sample subsets.
www.nature.com/scientificreports/
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proteins which were identified to be of interest included the cellular migration and invasion related actin-binding 
protein Swiprosin-1 (EFHD2) (Rsc -4.1), the drug resistance-related proteins Glyoxalase 1 (GLO1) (Rsc -3.1) 
and actin-binding protein Trangelin-2 (TAGLN2) (Rsc -3.0) cellular metabolism-related protein Enoyl-CoA 
Hydratase 1 (ECHS1) (Rsc -3.7) and cytosketelal as well as extracellular remodelling proteins PLEC (Rsc -1.1) 
and VIM (Rsc -1.2). A full list of down-regulated cellular proteins and their proposed cancer-related classifica-
tions are listed in Table 2 and summarised in Fig. 3a.
Up regulated cellular proteins in HEY Oct4A KD samples. Compared to HEY vector control samples, a total 
of 16 differentially up regulated cellular proteins were identified in HEY Oct4A KD samples (Fig. 1). Proteins 
which are categorised to be associated with cytoskeleton, tumor suppression, cellular growth, as well as those 
involved in lipid metabolism and drug resistance were identified as the most frequently up regulated in HEY 
Oct4A KD cellular samples (Fig. 3b, Table 3). The most significantly differential expressed cellular protein iden-
tified in HEY Oct4A KD samples was the cytoskeleton-related actin binding protein Plastin-1 (PLS1) (Rsc 7.1). 
Other up regulated cellular proteins which were identified included the cytoskeletal-related actin binding protein 
Twinfilin-1 (TWF1) (Rsc 5.1), and the tumor suppression-related proteins Apolipoprotein A-1 (APOA1) (Rsc 
5.1) and Eukaryotic release factor 1 (ETF1) (Rsc 2.3). A list of up regulated cellular proteins and their proposed 
cancer-related classifications are described in Table 3 and summarised in Fig. 3b.
Proposed protein functions of differentially expressed HEY Oct4A KD secreted proteins. Down 
regulated secreted proteins in HEY Oct4A KD samples. Analysis of the secretome revealed a total of 28 proteins 
were differentially suppressed in HEY Oct4A KD samples compared to HEY vector control samples (Fig. 1). 
When classified according to their function, a large number of proteins were found to be involved in cytoskele-
tal functions and cellular growth (Table 4). This was followed by proteins known to be involved with the ECM, 
CSCs, cellular adhesion and drug resistance. Of the identified down regulated secreted proteins, the ECM-related 
protein Fibronectin 1 (FN1) was the most significantly differentially expressed protein in HEY Oct4A KD sam-
ples (Rsc -15.3). This was closely followed by the ECM-related protein Laminin subunit gamma-2 (LAMC2) 
(Rsc -10.2). Other down regulated secreted proteins which were identified to be of interest included the 
ECM-related protein Laminin subunit beta-3 (LAMB3) (Rsc -7.8), the cytoskeleton cellular invasion-associated 
protein PLEC (Rsc -6.7), the CSC-associated protein CD109 antigen (CD109) (Rsc -5.0) and the drug 
resistance-related protein and protein identified as concurrently down-regulated in HEY Oct4A KD cellular sam-
ples Transgelin-2 (TAGLN2) (Rsc -4.7). Secreted proteins suppressed in HEY Oct4A KD samples and their 
proposed cancer-related functions are listed in Table 4 and summarised in Fig. 3a.
Up regulated secreted proteins in HEY Oct4A KD samples. Twenty-eight secreted proteins were differentially 
over-expressed in HEY Oct4A KD conditioned media samples when compared to HEY vector control samples 
(Fig. 1). Secreted proteins which were identified to have functional roles in cytoskeletal regulation, tumor sup-
pression and cellular growth were found to be the most significantly up regulated in HEY Oct4A KD samples 
Category Gene Name Protein Description Rsc *Reference
Cytoskeletal
TUBB2A Tubulin beta-2A chain - 42.9 (McCarroll and Kavallaris, 2012)
ACTC1 Alpha-cardiac actin - 1.7 (Tondeleir et al., 2011)
ACTB Beta-actin - 1.5 (Guo et al., 2013)
PLEC Plectin - 1.2 (Katada, K., et al., 2012)
Epithelial-Mesenchymal 
Transition
YWHAE 14-3-3ε - 10.0 (Liu et al., 2013a)
PPP2CA Serine/threonine-protein phosphatase 2A catlytic subunit alpha isolform - 3.3 (Bhardwaj et al., 2014)
VIM Vimentin - 1.2 (Mendez et al., 2010)
Cellular metabolism
ECHS1 Enoyl-CoA Hydratase 1 - 3.7 (Carracedo et al., 2013)
SLC25A3 Solute carrier damily 25 member 3 - 2.4 (Palmieri, 2013)
CS Citrate synthase - 2.4 (Gaude and Frezza, 2014)
Cellular migration/motility
EFHD2 Swiprosin-1 - 4.1 (Huh et al., 2015)
PFN1 Profilin-1 - 1.8 (Ding et al., 2012)
Drug resistance
GLO1 Glyoxalase 1 - 3.1 (Sakamoto et al., 2000)
TAGLN2 Transgelin-2 - 3.0 (Chen et al., 2014)
Protein transport SEC63 Translocation protein SEC63 homolog - 3.4 (Zimmermann et al., 2006)
Cell adhesion RSU1 Ras suppressor protein 1 - 2.8 (Kim et al., 2015b)
Immune response WARS Tryptophan-tRNA ligase, - 2.8 (Mellor and Munn, 1999)
Prognosticator of survival ALB Serum albumin - 1.8 (Gupta and Lis, 2010)
Post-translational 
modifications HIST1H4B Histone H4 - 1.6 (van der Meijden et al., 1998)
Table 2.  Down regulated cellular proteins in HEY Oct4A KD cells according to cellular function. Rsc: 
Protein abundance ratio (HEY Oct4A KD/HEY vector control). *Supplementary File 1.
www.nature.com/scientificreports/
7Scientific RepoRts | 7:46312 | DOI: 10.1038/srep46312
(Table 5). This was followed by proteins involved in oxidative stress response, inflammation and proteins used 
as prognosticators of survival. The most abundantly up regulated protein was the tumor suppressor-related 
protein HBB (Rsc 5.0). This was closely followed by the estrogen induced malignancy-associated protein 
Figure 3. Distribution of the potential biological functions of Oct4A protein targets in HEY Oct4A KD 
cells. The functions of the Oct4A protein targets obtained from the HEY Oct4A KD cells were searched in the 
literature and categorised according to their potential cancer-related biological functions. (a) Differentially 
expressed down regulated proteins are summarised as: (i) down regulated cellular proteins, (ii) down regulated 
secreted proteins, (iii) downregulated tumor xenograft proteins; (b) Differentially expressed up-regulated 
proteins are summarised as: (i) up-regulated cellular proteins, (ii) up-regulated secreted proteins, (iii) up-
regulated tumor xenograft proteins.
Category Gene Name Protein Description Rsc *Reference
Cytoskeletal
PLS1 Plastin-1 7.1 (Delanote et al., 2005)
TWF1 Twinfilin-1 5.1 (Moseley et al., 2006)
EPB41L2 Erythrocyte membrane protein band 4.1-like 2 4.5 (Lu et al., 2004)
Tumour suppression
APOA1 Apolipoprotein A-1 5.1 (Zamanian-Daryoush et al., 2013)
ETF1 Eukaryotic release factor 1 2.3 (Dubourg et al., 2002)
AHNAK Desmoyokin 1.8 (Lee et al., 2014)
Cellular growth/survival
TFRC Transferrin receptor protein 1 (CD71) 2.9 (Habashy et al., 2010)
DDX3X ATP-dependant RNA helicase DDX3X 2.6 (Lai et al., 2010)
EIF4A2 Eukaryotic initiation factor 4A2 1.8 (Modelska et al., 2015)
Drug resistance
TYMS Thymidylate synthase (EC 2.1.1.45) 5.1 (Wang et al., 2007)
ATP1A1 Sodium pump subunit alpha-1 1.8 (Stordal et al., 2012)
Lipid metabolism
NCEH1 Neutral cholestrol ester hydrolase 1 3.8 (Chiang et al., 2006)
PRIC295 Peroxisome proliferator activated receptor interacting complex protein 2.6 (Pyper et al., 2010)
Extracellular matrix PLOD2 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 2.1 (Gilkes et al., 2013)
Drug sensitivity PEBP1 (RKIP) Phosphatidylethanolamine-binding protein 1 1.9 (Li et al., 2014a)
Immune response FLNC Filamin-C 1.4 (Marti et al., 1997)
Table 3.  Up regulated cellular proteins in HEY Oct4A KD cells. Rsc: Protein abundance ratio (HEY Oct4A 
KD2/HEY vector control). *Supplementary File 1.
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Thyroxine-binding globulin (SERPINA7) (Rsc 4.7). Other up-regulated secreted proteins of interest included 
the immune response-associated protein Pentraxin-related protein 3 (PTX3) (Rsc 4.1), the oxidative stress 
response-related protein Glutathione S-transferase phosphate 1 (GSTP1) (Rsc 3.3) and the apoptosis-related pro-
tein POTE ankyrin domain family member F (POTEF) (Rsc 2.6). Similar to that identified in HEY Oct4A KD 
cellular samples, the tumor suppression-associated protein Apolipoprotein A1 (APOA1) was also up regulated 
in conditioned media preparations of HEY Oct4A KD samples compared to HEY vector control samples (Rsc 
4.3). Up regulated secreted proteins and their proposed cancer-related classifications are listed in Table 5 and 
summarised in Fig. 3b.
Proposed protein functions of differentially expressed HEY Oct4A KD xenograft tumor pro-
teins. Down regulated xenograft tumor proteins in HEY Oct4A KD samples. A total of 72 proteins were 
differentially suppressed in xenograft tumors derived from HEY Oct4A KD cells when compared to xenograft 
tumour samples derived from HEY vector control cells (Fig. 1). The increased number of proteins identified to 
be decreased in tumor xenograft samples resulted in an extensive list of protein function categories. Proteins 
which fit into the categories of cellular growth, cellular invasion, drug resistance, apoptosis, cytoskeletal and CSCs 
were identified as the most frequently down regulated proteins in HEY Oct4A KD tumor xenograft samples. 
This was followed by proteins which were involved in cellular adhesion, EMT, cellular metabolism and tumor 
suppression. The most down regulated protein identified in HEY Oct4A KD xenograft tumor samples was the 
cytoskeleton-associated protein TUBB2A (Rsc -78.1). This was followed by the cellular adhesion-associated 
proteins FN1 (Rsc -57.2) and FN cleaved into Anastellin (Rsc -55.4). Other down regulated proteins of inter-
est in tumor xenografts derived from HEY Oct4A KD cells included the CSC-associated proteins CD109 anti-
gen (CD109) (Rsc -12.8) and Pyruvate dehydrogenase E1 component subunit beta (PDHB) (Rsc -11.9), the 
EMT-related proteins Transforming growth factor-beta-induced protein (TGFβ 1) (Rsc -12.8) and Plastin-3 
Category
Gene 
Name Protein Description Rsc *Reference
Cytoskeletal
TUBB2A Tubulin beta-2A chain (Tubulin beta class IIa) - 8.0 (McCarroll and Kavallaris, 2012)
APLP2 Amyloid-like protein 2 - 5.8 (Pandey et al., 2015)
RDX Radixin - 5.6 (Hoeflich and Ikura, 2004)
FLNB Filamin-B - 5.0 (Popowicz et al., 2006)
FLNA Filamin-A - 4.5 (Popowicz et al., 2006)
ACTN2 Alpha-actinin-2 - 4.5 (Djinovic-Carugo et al., 2002)
Cellular growth/survival
UBA1 Ubiquitin-like modifier-activating enzyme 1 - 5.6 (Moudry et al., 2012)
EIF4A2 Eukaryotic initiation factor 4A-II - 4.7 (Modelska et al., 2015)
XPO1 Exportin-1 - 3.6 (van der Watt et al., 2009)
CTSD Cathepsin D (EC 3.4.23.5) - 3.4 (Langhoff et al.)
CLTC Clathrin heavy chain 1 - 2.2 (McMahon and Boucrot, 2011)
Extracellular matrix
FN1 FN1 protein (Fibronectin 1) - 15.3 (Singh et al., 2010)
LAMC2 Laminin subunit gamma-2 - 10.2 (Garg et al., 2014)
LAMB3 Laminin subunit beta-3 - 7.8 (Aumailley, 2013)
APP A4 Amyloid beta A4 protein - 3.2 (Klier et al., 1990)
Drug resistance
FASN Fatty acid synthase (EC 2.3.1.85) - 5.3 (Wu et al., 2014)
TAGLN2 Transgelin-2 - 4.7 (Chen et al., 2014)
PSAT Phosphoserine aminotransferase (EC 2.6.1.52) - 3.4 (Vie et al., 2008)
Cellular adhesion
PPIB Peptidyl-prolyl cis-trans isomerase B (cyclophilin B) - 4.5 (Melchior et al., 2008)
FN1 FN Fibronectin (Cleaved into: Anastellin) - 2.9 (Mercurius and Morla, 2001)
VCL Vinculin (Metavinculin) - 2.8 (Demali, 2004)
Cancer stem cells
CD109 CD109 antigen - 5.0 (Emori et al., 2013)
ANPEP Aminopeptidase N - 2.8 (Kim et al., 2012a)
Immune response
LTA4H Leukotriene A-4 hydrolase - 4.7 (Chen et al., 2004)
AEBP1 Adipocyte enhancer-binding protein 1 - 3.2 (Holloway et al., 2012)
Cellular invasion PLEC Plectin - 6.7 (Katada et al., 2012)
Angiogenesis TIE1 Tyrosine-protein kinase receptor Tie-1 (EC 2.7.10.1) - 3.4 (Jones et al., 2001)
Epithelial-Mesenchymal 
Transition DRIP4
Dopamine receptor interacting 
protein 4 - 2.8 (Ji et al., 2015)
Table 4.  Down regulated secreted proteins in HEY Oct4A KD cells. Rsc: Protein abundance ratio (HEY 
Oct4A KD2/HEY vector control). *Supplementary File 1.
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(PLS3) (Rsc -4.7), the cellular adhesion-associated proteins integrin-linked protein kinase (ILK) (Rsc -5.6) 
and intergin alpha-2 (ITGA2) (Rsc -2.9), the cellular migration and invasion-associated proteins PLEC 
(Rsc -3.2), (VIM) (Rsc -2.3) and Annexin 6 (ANXA6) (Rsc -2.9) and the angiogenesis-related protein 
Thioredoxin Reductase 1 (TXNRD1) (Rsc -4.7). Down regulated xenograft related proteins and their proposed 
cancer-related classifications are listed in Table 6 and summarised in Fig. 3b.
Up regulated xenograft tumor proteins in HEY Oct4A KD samples. Thirty-nine proteins were identified to be 
differentially elevated in tumor xenografts derived from HEY Oct4A KD cells compared to tumors derived from 
HEY vector control cells. Xenograft proteins which were identified to have functional roles in cellular growth, 
cellular metabolism, apoptosis, tumor suppression and oxidative stress response were the most frequently up 
regulated in HEY Oct4A KD tumor xenografts. This was followed by proteins involved with the cytoskeleton, 
calcium homeostasis and drug resistance. The most up regulated protein identified in HEY Oct4A KD xenograft 
tumor samples was the apoptosis-associated protein POTEF (Rsc 23.0). Other up regulated tumor xenograft 
proteins identified to be of interest included the tumor suppression-related protein Alpha amylase (AMY2A) 
(Rsc 7.3), the cellular growth-associated protein Eukaryotic translation initiation factor 4A2 (EIF42A) (Rsc 
5.9), the drug resistance-associated protein Collagen alpha 3 (VI) chain (COLGA3) (Rsc 3.7) and the cellular 
metabolism-related protein Isocitrate dehydrogenase (IDH2) (Rsc 2.5). Up regulated xenograft tumor proteins 
and their proposed cancer-related classifications are listed in Table 7 and summarised in Fig. 3b.
Proteome data network and pathway analysis. To identify protein networks and clusters associated with differen-
tially expressed proteome profiles from HEY vector control and Oct4A KD cellular (41 significantly differentially 
expressed proteins), secretome (59 significantly differentially expressed proteins) and xenograft (57 signifi-
cantly differentially expressed proteins), we performed protein-protein interaction analyses by STRING 10.033 
(Fig. 4a–c). Several clusters of interacting proteins in vector control compared to Oct4A KD cells were observed, 
including focal adhesion, adheren junctions, cytoskeleton, extracellular region, and cell junction protein networks 
(Fig. 4a), while for the secretome several clusters of interacting proteins in vector control compared to Oct4A KD 
cells included regulation of actin cytoskeleton, focal adhesion, and tubulin protein networks (Fig. 4b). On the 
Category Gene Name Protein Description Rsc *Reference
Cytoskeletal
TUBB2C Tubulin beta-2C 2.3 (McCarroll and Kavallaris, 2012)
TUBB4A Tubulin beta-4 chain 2.5 (McCarroll and Kavallaris, 2012)
TUBB5 Tubulin beta-5 chain 1.7 (McCarroll and Kavallaris, 2012)
TUBB6 Tubulin beta-6 chain 2.1 (McCarroll and Kavallaris, 2012)
ACTC1 Actin, alpha cardiac muscle 1 2.3 (Tondeleir et al., 2011)
ACTB Beta Actin 2.3 (Guo et al., 2013)
Tumour suppression
HBB Mutant beta-globin 5.0 (Onda et al., 2005)
APOA1 Apolipoprotein A1 4.3 (Zamanian-Daryoush et al., 2013)
ITIH3 Inter-alpha-trypsin inhibitor heavy chain H3 3.3 (Paris et al., 2002)
ITIH2 Inter-alpha (Globulin) inhibitor H2 3.1 (Hamm et al., 2008)
A2M Alpha-2-macroglobulin 3.3 (Lindner et al., 2010)
Cellular growth/survival
HSP90AA1 Heat shock protein HSP 90-alpha 2.0 (Chu et al., 2013)
SERPINE1 Plasminogen activator inhibitor 1.8 (Gomes-Giacoia et al., 2013)
HSPA8 Heat shock cognate 71 kDa protein 1.6 (Rohde et al., 2005)
HSP90AB1 Heat shock protein HSP 90-beta 1.5 (Haase and Fitze, 2015)
Oxidative stress response
GSTP1 Glutathione S-transferase P 3.3 (Kanwal et al., 2014)
HPX Hemopexin 2.9 (Tolosano and Altruda, 2002)
HBA1 Hemoglobin subunit alpha 2.7 (Li et al., 2013c)
Prognosticator of survival
ALB Serum albumin 4.3 (Gupta and Lis, 2010)
AFP Alpha-fetoprotein 3.1 (Li et al., 2013a)*
Immune response
PTX3 Pentraxin-related protein PTX3 4.1 (Bonavita et al., 2015)
C4A Complement C4-A 2.7 (Pio et al., 2013)
Cellular invasion
ANXA1 Annexin A1 4.7 (Cheng et al., 2012)
ANXA2 Annexin A2 3.3 (Lokman et al., 2013)
Estrogen-induced malignancy SERPINA7 Thyroxine-binding globulin 4.7 (Doe et al., 1967)
Angiogenesis APOB Apolipoprotein B-100 3.9 (Avraham-Davidi et al., 2012)*
Apoptosis POTEF POTE ankyrin domain family member F 2.6 (Liu et al., 2009)
Iron transport TF Transferrin 2.5 (Kovac et al., 2011)
Table 5.  Up regulated secreted proteins in HEY Oct4A KD cells. Rsc: Protein abundance ratio (HEY Oct4A 
KD2/HEY vector control). *Supplementary File1.
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Category Gene Name Protein Description Rsc *Reference
Cellular growth
BCAT1 Branched chain amino acid aminotransferase - 10.1 (Wang et al., 2015b)
PPP1CB Serine/threonine-protein phosphatase PP1-beta subunit - 7.4 (Velusamy et al., 2013)
MTHFD1L Monofunctional C1-tetrahydrofolate synthase - 5.6 (Tedeschi et al., 2013)
RPL13 60S ribosomal protein L13 - 4.7 (Kobayashi et al., 2006)
CAP1 hCG_2033246 Adenylyl cyclase-associated protein - 4.6 (Hua et al., 2015)
TMPO (LAP2)
Lamina-associated polypeptide 
2, isoform alpha Thymopoietin 
isoform alpha
- 3.2 (Brachner and Foisner, 2014)
CLTC Calathrin heavy chain 2 - 2.7 (McMahon and Boucrot, 2011)
HSPA1A Heat shock 70 kDa protein 1A/1B - 1.3 (Wu et al., 2012)
HSP90AB1 Heat shock protein HSP 90-beta - 1.3 (Haase and Fitze, 2015)
PABPC4 Poly(A) binding protein 4 - 1.3 (Katzenellenbogen et al., 2010)
HIST1H2BD Histone H2B type 1-D - 1.3 (Maruyama et al., 2014)
Cellular invasion
PDLIM1 LIM domain protein 1 - 10.1 (Liu et al., 2015c)
FAM49B Protein FAM49B - 7.6 (Sung et al., 2014)
DPYSL3 Dihydropyrimidinase-related protein 3 - 6.5 (Hiroshima et al., 2013)
GNAI3 Guanine nucleotide-binding protein G subunit alpha 3 - 4.7 (Zhang et al., 2015)*
PLEC Plectin - 3.2 (Katada et al., 2012)
ANXA6 Annexin A6 - 2.9 (Sakwe et al., 2011)*
CA3
Carbonic anhydrase 3 (EC 
4.2.1.1) (Carbonic anhydrase III) 
(CA-III)
- 1.7 (Dai et al., 2008a)
ANXA2 Annexin A2 - 1.6 (Lokman et al., 2013)
ALDOA Fructose-bisphosphate aldotase A - 1.4 (Sun et al., 2014)
ANXA1 Annexin A1 - 1.4 (Cheng et al., 2012)
FKBP1A Peptidyl-prolyl cis-trans isomerase -1.1 (Fong et al., 2003)
Drug resistance
CAPN2 Calpain-2 - 9.1 (Storr et al., 2012)
DYNC1H1 Cytoplasmic dynein 1 heavy chain 1 - 8.5 (Huang et al., 2014)
PSMD1 26S proteasome regulatory subunit RPN2 - 7.4 (Honma et al., 2008)
PRKDC DNA-dependent protein kinase catalytic subunit - 3.9 (Helleday et al., 2008)
TGM2 Protein -glutamine gamma-glutamyltransferase 2 - 2.7 (Cao et al., 2008)
HMGB1 High mobility group protein B1 - 1.7 (Huang et al., 2012a)
PEBP1(RKIP) Phosphatidylethanolamine-binding protein 1 - 1.7 (Liu et al., 2015a)
MDH2 Malate dehydrogenase - 1.5 (Lo et al., 2015)
HSP90AA1 Heat shock protein HSP 90-alpha - 1.3 (Chu et al., 2013)
Apoptosis
RLI RNase L inhibitor - 8.1 (Li et al., 2014b)
SLC25A6 ADP/ATP translocase 3 (ANT3) - 7.4 (Yang et al., 2007)
LRPPRC Leucine-rich PPR motig containing protein - 5.1 (Zhou et al., 2014)*
SMC3 Structural maintenance of chromosome 3 - 4.7 (Ghiselli, 2006)*
COPA Coatomer subunit alpha - 4.6 (Sudo et al., 2010)*
MAGED2 Melanoma-associated antigen D2 - 3.8 (Tseng et al., 2012)*
NT5E (CD73) 5′ -nucleotidase - 1.3 (Zhi et al., 2010)*
Cancer stem cells
CD109 Cluster of differentiation 109 - 12.8 (Emori et al., 2013)
PDHB Pyruvate dehydrogenase E1 component subunit beta - 11.9 (Anderson et al., 2014)
ALDH18A1 Aldehyde dehydrogenase family 18 member A1 - 3.8 (Buijs et al., 2012)
NES hCG_1999207 Nestin isoform CRA - 1.1 (Neradil and Veselska, 2015)
Continued
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other hand, tumor xenograft samples included clusters of interacting proteins regulating metabolic processes 
(carboxylic acid, oxoacid, and carbohydrate), extracellular region, and cytoskeleton protein networks (Fig. 4c).
Validation of candidate proteins by RT-PCR and immunohistochemistry. To validate the expression of selected 
proteins from proteomic profiling between the HEY Oct4A vector control and HEY Oct4A KD populations, 
RT-PCR and immunohistochemistry were carried out on a subset of proteins (TUBB2A, PLEC, VIM) in Oct4A 
vector control and Oct4A KD cells and associated xenografts (Fig. 5a and b). The three proteins selected for vali-
dation were significantly down regulated in HEY Oct4A KD cells and KD-derived xenografts compared to vector 
control cells and associated xenografts (Suppl Table 1). These proteins were chosen as they have known significant 
role in cytoskeletal and ECM reprogramming of cancer cells (Suppl File 1).
For RT-PCR analysis, the expression of Oct4A was significantly greater in HEY vector control compared 
to HEY KD cells (Fig. 5a). This elevated expression of Oct4A was consistent with the immunohistochemistry 
staining of det4in HEY Oct4A vector control compared to HEY Oct4A KD cell-derived xenografts (Fig. 5b). 
Consistent with that, RT-PCR analysis also showed consistent down regulation of TUBB2A, PLEC and VIM in 
HEY Oct4A KD compared to Oct4A vector control cell lysates (Fig. 5a). The down regulation of TUBB2A, PLEC 
and VIM in KD cell lysates was coherently observed in Oct4A KD cells-derived xenografts compared to vector 
control cell-derived xenografts. These validations of the differential expression of Oct4A, TUBB2A, PLEC and 
Category Gene Name Protein Description Rsc *Reference
Cytoskeletal
TUBB2A Tubulin beta-2A chain - 78.1 (McCarroll and Kavallaris, 2012)
CD2AP Adaptor protein CMS - 6.5 (Lynch et al., 2003)
TUBB4A Tubulin beta 4 A chain - 1.9 (McCarroll and Kavallaris, 2012)
TUBB5 Tubulin beta 5 chain - 1.7 (McCarroll and Kavallaris, 2012)
Cellular adhesion
FN1 FN Fibronectin (Cleaved into: Anastellin) - 55.4 (Mercurius and Morla, 2001)
ILK Integrin-linked protein kinase - 5.6 (Wang and Basson, 2009)
ITGA2 Integrin alpha-2 - 2.9 (Van Slambrouck et al., 2009)
Cellular metabolism
HIST2H2BE Histone H2B type 2-E - 46.3 (Dai et al., 2008b)
PFKP Phosphofructo-1-kinase isozyme C - 10.1 (Moon et al., 2011)
YARS2 Tyrosyl tRNA synthetase - 3.8 (Riley et al., 2010)
Epithelial-
Mesenchymal 
Transition
TGFB1 Transforming growth factor-beta-induced protein - 12.8 (Xu et al., 2009a)
HNRNPM Heterogeneous ribonucleoprotein M - 5.8 (Xu et al., 2014)
PLS3 Plastin-3 - 4.7 (Sugimachi et al., 2014)
Transcriptional 
regulation
RUVBL2
RuvB-like 2 (EC 3.6.4.12) (48 kDa 
TATA box-binding protein-
interacting protein)
- 7.4 (Flavin et al., 2011)
COPS7A Signalosome subunit 7a - 5.6 (Singer et al., 2014)
HNRNPD
Heterogeneous nuclear 
ribonucleoprotein D0 (hnRNP 
D0) (AU-rich element RNA-
binding protein 1)
- 1.5 (Moore et al., 2014)
DNA repair
RECQL ATP-dependant DNA helicase Q1 - 11.0 (Kawabe et al., 2000)
UBA1 Ubiquitin-activating enzyme E1 - 1.1 (Moudry et al., 2012)
Tumour suppression
MAP1B Microtubule-associated protein 1B - 5.6 (Lee et al., 2008)*
AHNAK Desamoyokin - 3.5 (Lee et al., 2014)*
OGDH 2-oxoglutarate dehydrogenase - 1.1 (Tennant and Gottlieb, 2010)
Angiogenesis
TXNRD1 Thioredoxin reductase 1 - 4.7 (Welsh et al., 2002)
AARS Alanine tRNA ligase - 4.7 (Mirando et al., 2015)
Protein transport
VPS35 Vacuolar protein sorting-associated protein 35 - 3.0 (Seaman et al., 1997)
EEA1 Early endosome antigen 1 - 2.2 (Christoforidis et al., 1999)
Extracellular matrix FN1 Fibronectin 1 Protein - 57.2 (Singh et al., 2010)
Carcinogen 
detoxification CYB5R3
NADH-cytochrome b5 reductase 
3 (Diaphorase-1) - 14.6 (Kurian et al., 2006)
Immune Response LTA4H Leukotriene A-4 hydrolase - 10.6 (Chen et al., 2004)
Cellular migration/
motility KTN1
KTN1 protein (highly similar to 
Kinectin) - 5.6 (Zhang et al., 2010b)
Unknown function TMPO hCG_2015322 Thymopentin isoform CRA_d - 2.7 Peer reviewed information could not be found
Table 6.  Down regulated proteins in HEY Oct4A KD tumor xenografts. Rsc: Protein abundance ratio (HEY 
Oct4A KD2/HEY vector control). *Supplementary File 1.
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VIM at the mRNA and protein levels in cell lysates and the xenografts is in harmony with the comprehensive 
proteomics data demonstrated in this study.
Functional association of Oct4A with TUBB2A, PLEC and VIM in drug resistance models. We have previously 
shown that the expression of Oct4/Oct4A is significantly enhanced in ovarian cancer cells in response to pacl-
itaxel and cisplatin treatments3,4,27. In this study we demonstrate that the elevation of Oct4A at the mRNA level 
correlates with the enhancement in TUBB2A, PLEC and VIM expression in parental HEY, SKOV3 and OVCAR5 
ovarian cancer cell lines in response to paclitaxel or cisplatin treatments (Fig. 6). This proof of concept observa-
tion consistently supports the functional association of Oct4A expression with key cytoskeletal/ECM associated 
proteins in ovarian cancer cell lines other than HEY cell line and suggests potential validity of this association in 
other tumor models.
Category Gene Name Protein Description Rsc *Reference
Cellular metabolism
GOT1 Aspartate aminotransferase 2.0 (Lyssiotis et al., 2013)
PYGB Phosphorylase (EC 2.4.1.1) 1.5 (Willmann et al., 2015)
GOT2 Glutamic-oxaloacetic transaminase 2 1.1 (Lyssiotis et al., 2014)
IDH2 Isocitrate dehydrogenase 2.5 (Borodovsky et al., 2012)
ATP5O ATP synthase subunit O 1.3 (Antoniel et al., 2014)
Cellular growth
EIF42A Eukaryotic translation initiation factor 4A2 5.9 (Modelska et al., 2015)
CKB Creatine kinase B-type 3.7 (Li et al., 2013b)
PCBP2 hCG_2017557 Poly(RC) binding protein 2 1.3 (Hu et al., 2014a)
TOMM34 Mitochondrial import receptor subunit TOM34 1.3 (Shimokawa et al., 2006)
Apoptosis
POTEF POTE ankyrin domain family member F 23.0 (Liu et al., 2009
HSPH1 Heat shock protein 105 kDa 1.5 (Kennedy et al., 2014)
HNRNPH3 Heterogeneous nuclear ribonucleoprotein H3 1.4 (Garneau et al., 2005)
COMT Catechol-O-methyltransferase 1.1 (Wu et al., 2015b)
Tumour suppression
AMY2A Alpha amylase 7.3 (Kang et al., 2010)
HBB Mutant beta-globin 1.9 (Onda et al., 2005)
KRBA2 KRAB-A domain-containing protein 1.7 (Li et al., 2003)
TPM1 Tropomyosin-1 1.2 (Bharadwaj and Prasad, 2002)
Oxidative stress response
NUDT5 ADP-sugar pyrophosphatase 3.1 (McLennan, 2006)
DNAJB11 DnaJ homolog subfamily B member 11 1.3 (Nakanishi et al., 2004)
HBA1 Alpha-globin 1.2 (Li et al., 2013c)
KPNA3 Karyopherin subunit alpha-3 1.0 (Young et al., 2013)
Cytoskeletal
NEB Nebulin 1.9 (Pappas et al., 2011)
TPM2 Tropomyosin-2 1.1 (Assinder et al., 2010)
Calcium homeostasis
ATP2A1 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 5.6 (Arbabian et al., 2011)
ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 4.1 (Arbabian et al., 2011)
Prognosticator of survival
ALB Serum albumin 3.7 (Gupta and Lis, 2010)
HP Haptoglobin (Zonulin) 3.0 (Zhao et al., 2007)*
Drug resistance
COL6A3 Collagen alpha-3(VI) chain 3.7 (Chen et al., 2013b)
TPI1 Triosephosphate isomerase 1 1.0 (Wang et al., 2008)*
Iron transport TF Transferrin 3.7 (Kovac et al., 2011)
Angiogenesis FMOD Fibromodulin 3.7 (Jian et al., 2013)
Cancer stem cells ANPEP Aminopeptidase N 1.1 (Kim et al., 2012a)
mRNA regulation NHP2L1 NHP2-like protein 1 2.1 (Esteller, 2011)
Cellular adhesion PRELP Prolargin 2.0 (Bengtsson et al., 2002)
Protein synthesis RPS17L 40S ribosomal protein S17 1.7 (Chen and Roufa, 1988)
Immune response FLNC Filamin-C 1.3 (Marti et al., 1997)
Cellular migration/motility BGN Biglycan 1.2 (Hu et al., 2014b)
Table 7.  Up regulated proteins in HEY Oct4A KD tumor xenografts. Rsc: Protein abundance ratio (HEY 
Oct4A KD2/HEY vector control). *Supplementary File 1.
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Discussion
We have previously demonstrated that suppression of Oct4A in the HEY cell line is sufficient to impact on OC 
tumorigenesis, metastasis and chemoresistance. Characteristics which were notably affected included cellu-
lar proliferation, adhesion, migration, invasion, increased sensitivity to chemotherapy treatment and overall 
decreased tumor initiating ability and metastasis in mouse models27,34. These diverse ranges of cellular traits 
affected by Oct4A knockdown strongly indicate direct or indirect regulation of Oct4A by signalling pathways 
and/or molecular mechanisms. In fact, clues as to how Oct4A influences these physiological changes within 
HEY cell line has come from previous observations that several markers associated with the CSC-like phenotype 
(Lin28, Sox2, CD44 and EpCAM), cellular adhesion and signalling integrins (α 2, α 5, α 6, β 1 and CD44), cellular 
invasion (Pro-MMP2), proliferation (Ki67), angiogenesis (CD31 and CD34) and survival (Bcl2 and GLUT1) were 
significantly impacted in HEY cells following knockdown of Oct4A expression27,34. However, these studies did not 
provide direct evidence of Oct4A specific proteome-mediated molecular mechanisms which influenced such an 
accumulative variety of biological processes. Therefore, we employed label-free MS-based proteomics to investi-
gate the protein profiles between sample subsets (cell lysates and secretome and tumor xenografts) derived from 
HEY Oct4A KD and vector control cells to identify protein expression differences as a result of Oct4A regulation.
Overall, the data indicated Oct4A to be a key regulator of cytoskeleton/ECM remodelling besides its tumor-
igenic role that we have described previously27,34. Considering the extensive association of proteins identified, 
an effort was made to identify key proteins that regulate tumor-associated Oct4A traits in OC cells. Proteins 
which were consistently represented in the HEY Oct4A KD trait in each of the sample subsets were cytoskeleton 
proteins belonging to the tubulin, plakin and actin families. Of these TUBB2A, a member of the tubulin family 
and a major constituent of the cytoskeleton and critically involved in microtubule structure36 displayed concord-
ant down regulation in the cellular (- 42.9), xenograft (- 78.1), and secretome (- 8.0) subsets when Oct4A was 
down regulated. Besides TUBB2A, other members of tubulin family affected by Oct4A knockdown were TUBB6, 
TUBB2C, TUBB4A, TUBB4, TUBB5, which were prominently down regulated in Oct4A KD xenografts com-
pared to xenografts derived from vector control cells.
More recently, TUBB2A has been described as having a role in regulating neuronal proliferation and migration37. 
Changes in β -tubulin isotype composition have been associated with tumor response to paclitaxel38,39 and 
increased tumor expression of β -tubulin II has been strongly associated with poor outcome in patients with 
head and neck carcinoma treated with docetaxel, a paclitaxel analogue40. Furthermore, increased TUBB2A 
expression has been correlated with decreased drug sensitivity in paclitaxel-resistant breast cancer  cells41. This 
is consistent with our validation data which demonstrates a correlation of enhanced expression of TUBB2A with 
increased expression of Oct4A expression in paclitaxel or cisplatin treatment surviving resistant ovarian paren-
tal HEY, SKOV3 and OVCAR5 cell lines. Such evidence is also in agreement with our previous study, where 
we have demonstrated significant correlation between high Oct4A gene expression in recurrent OC patient’s 
ascites-derived tumor cells in response to treatment with a combination of cisplatin and paclitaxel compared to 
untreated (chemonaive) OC patient’s ascites derived tumor cells27.
Figure 4. Protein interaction network analysis of secreted differentially expressed proteins. Protein 
interaction network generated with STRING 10.0 for, (a) cellular, (b) secretome and (c) tumor xenograft and 
samples. Based on molecular high-confidence action and functional enrichments analysis, major clusters of 
interacting proteins include those involved in regulation of actin cytoskeleton, focal adhesion, and tubulin 
(secretome), focal adhesion, adherenes junctions, cytoskeleton, extracellular region, and cell junction protein 
networks (cellular), and metabolic processes (carboxylic acid, oxoacid, carbohydrate), extracellular region, and 
cytoskeleton (tumor xenograft).
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Among other cytoskeleton proteins, PLEC a member of plakin family was significantly down regulated in 
Oct4A knockdown tumor xenograft and secretomes42. PLEC links the intermediate filament VIM with cytoplas-
mic organelles, and also provides stabilisation and links to nuclear envelope and centrosomes43. Increased PLEC 
and VIM expression, through PLEC-VIM complex has also been correlated to the migratory and invasive pheno-
types in androgen-independent prostate and other cancers44–46. Loss of PLEC in HEY Oct4A KD cells coincides 
with the loss of VIM expression also seen in tumor xenografts. This is consistent with enhanced expression of 
PLEC and VIM in response to paclitaxel or cisplatin treatments in parental HEY, SKOV3 and OVCAR5 ovarian 
cell lines which coincided with elevated expression of Oct4A in these cells. This new finding adds novel clinical 
aspect of Oct4A regulation through key cytoskeletal and ECM proteins in the context of drug resistance, a major 
clinical hurdle for ovarian cancer patients.
The proteomic profiling of HEY Oct4A KD cells also demonstrated a loss of Mitogen activated protein kinase/
Extracellular signal regulated kinase (MAPK/ERK) pathway in Oct4A knocked down tumor xenografts and 
secretomes. PLEC have been linked with MAPK/ERK pathway with respect to the migratory biology of keratino-
cytes and head and neck squamous cancer46,47. It was proposed that interaction of PLEC with MAPK/ERK path-
way occurs due to interaction of PLEC with hemidesmosomal integrin α 6β 4, ligation of which by PLEC results 
in the activation of MAPK/ERK pathway48. Besides tubulin and plakins, actin-binding protein TAGLN2 involved 
with cancer cell motility and metastatic potential was also significantly decreased in HEY Oct4A KD samples49. 
These observations are consistent with decreased motility and metastatic potential of Oct4A KD cells that we have 
previously demonstrated27. On the other hand, actin-binding protein PLS1 and TWF1 involved with cell motility 
and mitotic division were significantly increased in HEY Oct4A KD samples. This increase in actin-binding PLS1 
and TWF150,51 may occur to compensate the decrease in cytoskeleton tubulins, plakins and TAGLN. However, 
this compensatory increase may not provide requisite level of signals to initiate the migratory and metastatic 
potentials in the absence of Oct4A signals.
We have recently shown that suppression of Oct4A in HEY cell line resulted in the loss of α v and α 2 family of 
integrins34. This observation is consistent with the proteomics data in the current study which showed a loss of α v 
and α 2 family of integrins and integrin-linked kinase (ILK) in the secretomes and tumor xenografts derived from 
HEY Oct4A KD cells compared to vector control cells derived secretomes and xenografts. ILK has previously 
been shown to regulate mitotic cytoskeleton dynamics in retinoblastomas52. Consistent with that we see loss of 
Figure 5. (a) Expression of Oct4A, TUBB2A, PLEC and VIM in HEY vector control and Oct4A KD cells. 
RNA from HEY vector control and HEY Oct4A KD cells was extracted, cDNA was prepared and RT-PCR 
was performed as described in the Materials and Methods. The resultant mRNA levels were normalized to 
18S mRNA. Results are representation of three independent experiments performed in triplicate. Significant 
variations between vector control and Oct4A KD cells was analysed by unpaired t-test with Welch’s correction 
using GraphPad Prism 7.02 and are indicated by *P < 0.05. (b) Expression of Oct4, TUBB2A, PLEC and 
VIM in mouse tumor xenografts generated by HEY vector control and Oct4A KD cells. Representative 
immunohistochemistry images of mouse xenografts for the expression of Oct4A, TUBB2A, PLEC and VIM. 
Images are set at 400x magnification and scale bar represents 60 μ M (c) Variations in staining were determined 
by subtracting the negative control DAB readings number of strong positivity (Nsp)/area from the DAB 
readings of protein of interest for each xenograft. Data is presented as the mean ± SEM.
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Figure 6. Expression of Oct4A, TUBB2A, PLEC and VIM in parental HEY, SKOV3 and OVCAR5 cell lines 
in response to paclitaxel or cisplatin treatment. (a) HEY, (b) SKOV3 and (c,d) OVCAR5 cell lines were treated 
with GI50 concentrations of paclitaxel or cisplatin for 72 hrs. RNA with and without paclitaxel or cisplatin 
treatments was extracted, cDNA was prepared and RT-PCR was performed as described in the Materials 
and Methods. The resultant mRNA levels were normalized to 18S mRNA. Results are representation of three 
independent experiments performed in triplicate. Significant variations between treated and untreated cells 
(control) was analysed by unpaired t-test with Welch’s correction using GraphPad Prism 7.02 and are indicated 
by *P < 0.05; **P < 0.01.
Figure 7. Proposed model of Oct4A regulation in ovarian carcinomas. Ovarian tumors contain high 
expression of Oct4A which promotes ovarian tumorigenesis27. Knockdown of Oct4A in ovarian cancer 
cells results in the down regulation of major regulatory network of proteins including those involved with 
cytoskeleton-ECM remodelling, proliferation and cellular growth, EMT, CSCs, cellular adhesion, drug 
resistance and cellular invasion. This promotes the diminution of tumorigenic phenotypes which we have 
shown in our previous studies13,27,34.
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Fibronectin (FN) and Laminin (LM) in the secretomes, and only loss of FN in the tumor xenografts derived from 
Oct4A KD cells compared to that derived from vector control cells. As FN and LM form important constituents of 
ovarian ECM and has significant roles in ovarian tumorigenesis53,54, it is likely that the loss of FN and LM in com-
bination with cytoskeletal PLEC, VIM and integrins contributes to the loss of tumorigenic and invasive potential 
of Oct4A KD cells in mouse models as reported in our previous studies27.
Protein secretion by ovarian tumor cells has been shown to result in autocrine and paracrine signalling that 
defines cell growth, migration and the makeup of extracellular environment55. Secretion of PLEC in extracellular 
cyst fluid has been identified as a biomarker for the detection of early intra-ductal papillary mucinous neoplasms, 
a group of lesions with varying metastatic potential often detectable by CT scan56. PLEC expression increases 
during the development of pancreatic intraepithelial neoplasia, pre-cursor lesions of invasive and metastatic pan-
creatic ductal adenocarcinoma (PDAC)57. In addition, secretory form of PLEC makes an important component 
of exosomes of pancreatic cancer cells where it couples with α 6β 4 integrin58. In contrast, pericellular FN has also 
been shown to promote the metastasis of lung cancer cells by adhering to the cell surface receptor dipeptidyl 
peptidase IV (DPP IV)59. Hence, loss of secretory FN and PLEC in response to Oct4A KD may contribute to loss 
of migration, in vivo invasion and tumor development that we have reported previously34.
Proteins found to be up regulated in HEY Oct4A KD were primarily associated with cellular survival. These 
categories included cellular proliferation, lipid metabolism, cellular metabolism, cellular growth and oxidative 
stress. This included cytoskeleton (e.g. TWF1), cellular growth (EIF42A), cellular metabolism (IDH2) and oxida-
tive stress (HBA1). Interestingly, despite the up regulation of these proteins, HEY Oct4A KD cells derived tumors 
displayed an overall reduced growth and tumorigenic potential in mouse models27,34. This may simply be due 
to the fact that up regulated proteins were not as strongly represented in HEY Oct4A KD samples compared to 
down regulated proteins. Logically, down regulated proteins may have a stronger influence on the phenotype of 
HEY Oct4A KD cells. However, it may also be that proteins which were up regulated are done as a compensatory 
mechanism for the stressful changes occurring in the overall phenotype of the HEY Oct4A KD cells. For instance, 
increased oxidative stress is a phenomenon shown to occur as a result to increased cellular metabolism60. Hence, 
cellular metabolism and oxidative stress proteins are strongly represented as up regulated in HEY Oct4A KD pro-
teins. This may suggest oxidative stress response proteins are being produced to compensate the elevated cellular 
metabolism occurring in Oct4A KD cells to sustain their survival. An altered cellular metabolism has been shown 
to occur in CSCs61,62. However, it remains unclear why HEY Oct4A KD cells undergo increased cellular metab-
olism and requires further analysis. However, proteins which appear to be involved in cellular apoptosis (e.g. 
POTEF) and tumor suppression (APOA1) were also noted to be up regulated following Oct4A suppression. This 
indicates that there may be some strong influence of pro-survival mechanisms in HEY cells following suppression 
of Oct4A expression. However, the up regulated proteins involved with cellular apoptosis and tumor suppression 
may have positive implications in reducing tumor growth and survival of HEY cells and may support the reduced 
tumor growth observed previously in HEY Oct4A KD cells both in vitro and in vivo27,34.
Conclusion
This study has for the first time identified the global proteome profile associated with Oct4A in ovarian can-
cer, targeting cellular, secretome and tumor xenograft subsets. These findings along with the validation of key 
cytoskeletal and ECM proteins (TUBB2A, PLEC, VIM) support the diminutive changes of proteins associated 
with cytoskeleton and ECM as major targets of Oct4A knockdown. In addition, gene/protein data using ICGC 
(International Cancer Genome Consortium, http://icgc.org), EBI Expression Atlas (http://www.ebi.ac.uk) and 
The Cancer Genome Atlas (https://gdc-portal.nci.nih.gov) which focused on ovarian tumors/tissues, suggest over 
expression of Oct4 in ovarian tumors. Furthermore, Oncomine (A Cancer Microarray Database and Integrated 
Data, https://www.oncomine.com/) indicates increased Oct4 gene expression (fold change 6.313) in ovarian tum-
ors in comparison to normal ovarian tissues. Even though VIM/PLEC/TUBB2A demonstrated high expression in 
ovarian tumors (top 1%), no comparison with normal ovarian tissue exists in these databases so no enrichment/
fold change can be indicated in tumors. These data support an association of Oct4A with cytoskeletal-ECM net-
work, the key findings of this large-scale proteomics study. The attenuation of tumorigenic phenotype of HEY 
cells resulting from the knock down of Oct4A shown in our previous study further support these findings27,34.
These observations are sustained in drug resistant models where up regulation of Oct4A in paclitaxel or cispla-
tin treatment surviving residual parental HEY, SKOV3 and OVCAR5 cell lines correlated with the up regulation 
of TUBB2A, PLEC and VIM expression. This is consistent with the network pathway analyses which identified 
cytoskeleton and ECM proteins to be significantly diminished in the target subsets. However, network pathway 
analyses also identified clusters of proteins regulating glycolysis(Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), Lactate dehydrogenase live type A (LDHA), Phospho fructo-kinase (PFK), Pyruvate dehydrogenase 
(PDH)) and (fatty acid synthesisFatty acid synthase (FASN)) to diminish in response to Oct4A knockdown. 
Overall, the protein changes observed are highly complex but the networks and results of this current proteomic 
analysis support the findings of our previous studies performed in vitro and in vivo13,27,34. The identified proteins 
described in this study have a strong implication in understanding Oct4A related functions in ovarian tumors in 
general and may apply in understanding Oct4A related functions in tumor models of other cancers. Based on this 
proteomic analysis a model of Oct4A regulation in ovarian carcinomas has been proposed in Fig. 7.
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